Intestinal microbiota is altered in patients with colon cancer and modified by probiotic intervention

From BugSigDB
Reviewed Marked as Reviewed by Claregrieve1 on 2022/10/29
study design
Citation
PMID PubMed identifier for scientific articles.
DOI Digital object identifier for electronic documents.
URI
Authors
Hibberd AA, Lyra A, Ouwehand AC, Rolny P, Lindegren H, Cedgård L, Wettergren Y
Journal
BMJ open gastroenterology
Year
2017
Keywords:
COLORECTAL CANCER, INTESTINAL MICROBIOLOGY, PROBIOTICS, TUMOUR MARKERS
OBJECTIVE: The colonic microbiota is altered in patients with colorectal cancer (CRC). We investigated the microbiota composition of patients with colon cancer compared with controls devoid of neoplastic or inflammatory disease and the potential to modify the colonic microbiota with probiotics. DESIGN: Biopsy samples were obtained from the normal mucosa and tumour during colonoscopy from 15 patients with colon cancer. Subsequent patient-matched samples were taken at surgery from the tumour and nearby mucosa from the patients with cancer, eight of whom had received two daily tablets totalling 1.4×1010 CFUs Bifidobacterium lactis Bl-04 and 7×109 CFUs Lactobacillus acidophilus NCFM. Faecal samples were obtained after colonoscopy prior to starting the intervention and at surgery. In addition, 21 mucosal biopsies from non-cancer controls were obtained during colonoscopy followed by later faecal samples. The colonic and faecal microbiota was assessed by 16S rRNA gene amplicon sequencing. RESULTS: The tumour microbiota was characterised by increased microbial diversity and enrichment of several taxa including Fusobacterium, Selenomonas and Peptostreptococcus compared with the control microbiota. Patients with colon cancer that received probiotics had an increased abundance of butyrate-producing bacteria, especially Faecalibacterium and Clostridiales spp in the tumour, non-tumour mucosa and faecal microbiota. CRC-associated genera such as Fusobacterium and Peptostreptococcus tended to be reduced in the faecal microbiota of patients that received probiotics. CONCLUSIONS: Patients with colon cancer harbour a distinct microbiota signature in the tumour tissue and nearby mucosa, which was altered with probiotic intervention. Our results show promise for potential therapeutic benefits in CRC by manipulation of the microbiota. TRIAL REGISTRATION NUMBER: NCT03072641; Results.

Experiment 1


Reviewed Marked as Reviewed by Claregrieve1 on 2022/10/29

Curated date: 2021/01/10

Curator: WikiWorks

Revision editor(s): Fatima, Claregrieve1, WikiWorks, ChiomaBlessing

Subjects

Location of subjects
Sweden
Host species Species from which microbiome was sampled. Contact us to have more species added.
Homo sapiens
Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology
Mucosa of ascending colon Ascending colon mucosa,Ascending colon mucosa of organ,Ascending colon mucous membrane,Ascending colon organ mucosa,Mucosa of organ of ascending colon,Mucous membrane of ascending colon,Organ mucosa of ascending colon,Mucosa of ascending colon,mucosa of ascending colon
Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
Colorectal cancer cancer of colorectum,cancer of large bowel,cancer of large intestine,cancer of the large bowel,colon cancer,colorectal cancer,colorectum cancer,CRC,large intestine cancer,malignant colorectal neoplasm,malignant colorectal tumor,malignant colorectum neoplasm,malignant large bowel neoplasm,malignant large bowel tumor,malignant large intestine neoplasm,malignant large intestine tumor,malignant neoplasm of colorectum,malignant neoplasm of large bowel,malignant neoplasm of large intestine,malignant neoplasm of the large bowel,malignant neoplasm of the large intestine,malignant tumor of large bowel,malignant tumor of large intestine,malignant tumor of the large bowel,malignant tumor of the large intestine,Colorectal cancer
Group 0 name Corresponds to the control (unexposed) group for case-control studies
control group
Group 1 name Corresponds to the case (exposed) group for case-control studies
colon cancer patients
Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
patients diagnosed with stage I-III colon cancer
Group 0 sample size Number of subjects in the control (unexposed) group
14
Group 1 sample size Number of subjects in the case (exposed) group
12
Antibiotics exclusion Number of days without antibiotics usage (if applicable) and other antibiotics-related criteria used to exclude participants (if any)
recent

Lab analysis

Sequencing type
16S
16S variable region One or more hypervariable region(s) of the bacterial 16S gene
V4
Sequencing platform Manufacturer and experimental platform used for quantifying microbial abundance
Illumina

Statistical Analysis

Data transformation Data transformation applied to microbial abundance measurements prior to differential abundance testing (if any).
relative abundances
Statistical test
Mann-Whitney (Wilcoxon)
Significance threshold p-value or FDR threshold used for differential abundance testing (if any)
0.05
MHT correction Have statistical tests be corrected for multiple hypothesis testing (MHT)?
Yes

Alpha Diversity

Richness Number of species
increased

Signature 1

Reviewed Marked as Reviewed by Claregrieve1 on 2022/10/29

Curated date: 2021/01/10

Curator: Fatima Zohra

Revision editor(s): Fatima, Claregrieve1, WikiWorks

Source: Table 2, supplemental table S1

Description: Microbiota alterations in colon cancer mucosa samples compared with non cancer control mucosa at colonoscopy

Abundance in Group 1: increased abundance in colon cancer patients

NCBI Quality ControlLinks
Bacteroidota
Bilophila
Clostridium
Dialister
Methanobacteriota
Fusobacteriota
Fusobacterium
Methanobrevibacter
Oscillospira
Peptostreptococcus
Mycoplasmatota

Revision editor(s): Fatima, Claregrieve1, WikiWorks

Signature 2

Reviewed Marked as Reviewed by Claregrieve1 on 2022/10/29

Curated date: 2021/01/10

Curator: Fatima Zohra

Revision editor(s): Fatima, Claregrieve1, WikiWorks

Source: Table 2, supplemental table S1

Description: Microbiota alterations in colon cancer mucosa compared with non cancer control mucosa at colonoscopy

Abundance in Group 1: decreased abundance in colon cancer patients

NCBI Quality ControlLinks
Streptococcus

Revision editor(s): Fatima, Claregrieve1, WikiWorks

Experiment 2


Reviewed Marked as Reviewed by Claregrieve1 on 2022/10/29

Curated date: 2021/01/10

Curator: WikiWorks

Revision editor(s): Claregrieve1, WikiWorks, ChiomaBlessing

Differences from previous experiment shown

Subjects

Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology
Colon Hindgut,Large bowel,Posterior intestine,Colon,colon
Group 1 name Corresponds to the case (exposed) group for case-control studies
colon cancer patients (tumor samples)

Lab analysis

Statistical Analysis

Alpha Diversity

Richness Number of species
increased

Signature 1

Reviewed Marked as Reviewed by Claregrieve1 on 2022/10/29

Curated date: 2021/01/10

Curator: Fatima Zohra

Revision editor(s): Claregrieve1, WikiWorks

Source: Table 2, supplemental table S1

Description: Microbiota alterations in colon cancer tumor samples compared with non cancer control mucosa at colonoscopy

Abundance in Group 1: increased abundance in colon cancer patients (tumor samples)

NCBI Quality ControlLinks
Methanobrevibacter
Peptostreptococcus
Selenomonas

Revision editor(s): Claregrieve1, WikiWorks

Experiment 3


Needs review

Curated date: 2021/01/10

Curator: WikiWorks

Revision editor(s): Claregrieve1, WikiWorks, ChiomaBlessing

Differences from previous experiment shown

Subjects

Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology
Feces Cow dung,Cow pat,Droppings,Dung,Excrement,Excreta,Faeces,Fecal material,Fecal matter,Fewmet,Frass,Guano,Matières fécales@fr,Merde@fr,Ordure,Partie de la merde@fr,Piece of shit,Porción de mierda@es,Portion of dung,Portion of excrement,Portion of faeces,Portion of fecal material,Portion of fecal matter,Portion of feces,Portion of guano,Portion of scat,Portionem cacas,Scat,Spoor,Spraint,Stool,Teil der fäkalien@de,Feces,feces
Group 1 name Corresponds to the case (exposed) group for case-control studies
colon cancer patients (fecal samples)
Group 0 sample size Number of subjects in the control (unexposed) group
21
Group 1 sample size Number of subjects in the case (exposed) group
14

Lab analysis

Statistical Analysis

Signature 1

Reviewed Marked as Reviewed by Claregrieve1 on 2022/10/29

Curated date: 2021/01/10

Curator: Fatima Zohra

Revision editor(s): Fatima, Claregrieve1, WikiWorks

Source: Supppemental table S2, text

Description: Microbiota alterations in colon cancer fecal samples compared with non cancer control fecal samples at colonoscopy

Abundance in Group 1: increased abundance in colon cancer patients (fecal samples)

NCBI Quality ControlLinks
Dorea
Peptostreptococcus

Revision editor(s): Fatima, Claregrieve1, WikiWorks

Signature 2

Needs review

Curated date: 2021/01/10

Curator: Fatima Zohra

Revision editor(s): Claregrieve1, WikiWorks

Source: Supppemental table S2

Description: Microbiota alterations in colon cancer fecal samples compared with non cancer control fecal samples at colonoscopy

Abundance in Group 1: decreased abundance in colon cancer patients (fecal samples)

NCBI Quality ControlLinks
Roseburia
Mycoplasmatota

Revision editor(s): Claregrieve1, WikiWorks